Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Marker Therapeutics (MRKR) over the last 11 years, with Q3 2025 value amounting to $9.9 million.

  • Marker Therapeutics' Cash from Financing Activities rose 57978730.16% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.8 million, marking a year-over-year increase of 2452790.09%. This contributed to the annual value of $15.0 million for FY2024, which is 125653.64% up from last year.
  • Latest data reveals that Marker Therapeutics reported Cash from Financing Activities of $9.9 million as of Q3 2025, which was up 57978730.16% from $100.0 recorded in Q2 2025.
  • Marker Therapeutics' Cash from Financing Activities' 5-year high stood at $52.7 million during Q1 2021, with a 5-year trough of -$100743.0 in Q2 2021.
  • In the last 5 years, Marker Therapeutics' Cash from Financing Activities had a median value of $49096.0 in 2024 and averaged $5.2 million.
  • Data for Marker Therapeutics' Cash from Financing Activities shows a peak YoY increase of 57978730.16% (in 2025) and a maximum YoY decrease of 9977.58% (in 2025) over the last 5 years.
  • Over the past 5 years, Marker Therapeutics' Cash from Financing Activities (Quarter) stood at -$100743.0 in 2021, then surged by 237.54% to $138557.0 in 2022, then plummeted by 96.29% to $5135.0 in 2023, then soared by 289985.9% to $14.9 million in 2024, then plummeted by 33.78% to $9.9 million in 2025.
  • Its last three reported values are $9.9 million in Q3 2025, $100.0 for Q2 2025, and $505.0 during Q1 2025.